Literature DB >> 12574370

TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.

Christian H Poehlein1, Hong-Ming Hu, Jane Yamada, Ilka Assmann, W Gregory Alvord, Walter J Urba, Bernard A Fox.   

Abstract

We have recently shown that effector T cells (T(E)) lacking either perforin or IFN-gamma are highly effective mediators of tumor regression. To rule out compensation by either mechanism, T(E) deficient in both perforin and IFN-gamma (perforin knockout (PKO)/IFN-gamma knockout (GKO)) were generated. The adoptive transfer of PKO/GKO T(E) mediated complete tumor regression and cured wild-type animals with established pulmonary metastases of the B16BL6-D5 (D5) melanoma cell line. PKO/GKO T(E) also mediated tumor regression in D5 tumor-bearing PKO, GKO, or PKO/GKO recipients, although in PKO/GKO recipients efficacy was reduced. PKO/GKO T(E) exhibited tumor-specific TNF-alpha production and cytotoxicity in a 24-h assay, which was blocked by the soluble TNFRII-human IgG fusion protein (TNFRII:Fc). Blocking TNF in vivo by administering soluble TNFR II fusion protein (TNFRII:Fc) significantly reduced the therapeutic efficacy of PKO/GKO, but not wild-type T(E). This study identifies perforin, IFN-gamma, and TNF as a critical triad of effector molecules that characterize therapeutic antitumor T cells. These insights could be used to monitor and potentially tune the immune response to cancer vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574370     DOI: 10.4049/jimmunol.170.4.2004

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.

Authors:  Meixiao Long; Aaron M Slaiby; Adam T Hagymasi; Marianne A Mihalyo; Alexander C Lichtler; Steven L Reiner; Adam J Adler
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

2.  Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.

Authors:  Justin Kline; Long Zhang; Lauren Battaglia; Kenneth S Cohen; Thomas F Gajewski
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

Review 3.  Immunotherapy for melanoma: the good, the bad, and the future.

Authors:  Christian H Poehlein; Dominik Rüttinger; Jun Ma; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

4.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

Review 5.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

6.  CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.

Authors:  Hui Zhao; Xueyan Xi; Lianxian Cui; Wei He
Journal:  Cell Mol Immunol       Date:  2011-09-12       Impact factor: 11.530

7.  Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.

Authors:  Irina Obleukhova; Nataliya Kiryishina; Svetlana Falaleeva; Julia Lopatnikova; Vasiliy Kurilin; Vadim Kozlov; Aleksander Vitsin; Andrey Cherkasov; Ekaterina Kulikova; Sergey Sennikov
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

8.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials.

Authors:  Meixiao Long; Amy D Higgins; Marianne A Mihalyo; Adam J Adler
Journal:  Cell Immunol       Date:  2003-08       Impact factor: 4.868

10.  Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Authors:  Patrycja Koszałka; Ewa Szmit; Andrzej Myśliwski; Jacek Bigda
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.